RecruitingPhase 1NCT07114367

NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

An Open-Label, Multicenter, Monotherapy, Dose-Escalation, Phase 1 Clinical Trial of NB02 (Posseltinib) in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Sponsor

NOBO Medicine

Enrollment

9 participants

Start Date

Dec 2, 2025

Study Type

INTERVENTIONAL

Conditions

Non-Hodgkin Lymphoma (NHL)

Summary

This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL

Eligibility

Min Age: 19 YearsMax Age: 80 Years

Inclusion Criteria7

Age 19 to 80 years.
Patients must voluntarily agree to participate in the study and provide written informed consent prior to any study-related procedures.
Patients with histologically confirmed follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma.
relapsed/refractory Patients who have received more than two prior lines of therapy.
Measurable disease based on Lugano classification.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
Adequate organ function including:

Exclusion Criteria7

Previous treatment with NB02 (poseltinib).
Patients who have experienced progression on BTKi mono or BTKi containing regimen (However, patients who discontinued treatment due to adverse-effect-related intolerance or for economic or social reasons remain eligible for enrollment).
Unable to take oral medication.
Inability to comply with study and follow-up procedures.
Concurrent use of other investigational drugs or enrollment in another clinical trial within 4 weeks prior to study drug administration.
Patients who have previously been treated with NB02 (poseltinib) or any other BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib).
Known HIV, HCV and HBV infection with active diseases